Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.
EGFR inhibitor
dacomitinib
overall survival
pharmacokinetics
progression-free survival
proton-pump inhibitors
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
17 Jan 2024
17 Jan 2024
Historique:
received:
25
10
2023
revised:
05
01
2024
accepted:
11
01
2024
medline:
23
1
2024
pubmed:
23
1
2024
entrez:
23
1
2024
Statut:
epublish
Résumé
Dacomitinib is an irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of patients with advanced non-small-cell lung cancer (NSCLC) and EGFR-activating mutations. Proton-pump inhibitors decreased dacomitinib exposure. This analysis summarizes the effect of Histamine-2 receptor antagonists (H2RAs) on dacomitinib exposure. A within-patient comparison of the steady-state trough concentrations (C
Identifiants
pubmed: 38258127
pii: pharmaceutics16010118
doi: 10.3390/pharmaceutics16010118
pii:
doi:
Types de publication
Journal Article
Langues
eng